Bronchospasm

Results: 16



#Item
1HYDROCORTISONE (SODIUM SUCCINATE) (A) (Revised: November[removed]TYPE:  Adrenocorticosteroid [S4]

HYDROCORTISONE (SODIUM SUCCINATE) (A) (Revised: November[removed]TYPE: Adrenocorticosteroid [S4]

Add to Reading List

Source URL: cdn.esa.act.gov.au

Language: English - Date: 2012-12-23 18:34:06
2CMG 9 - RESPIRATORY DISTRESS (Revised: January[removed]a) Bronchospasm Mild to Moderate: Salbutamol and Ipratropium puffer with spacer initially

CMG 9 - RESPIRATORY DISTRESS (Revised: January[removed]a) Bronchospasm Mild to Moderate: Salbutamol and Ipratropium puffer with spacer initially

Add to Reading List

Source URL: cdn.esa.act.gov.au

Language: English - Date: 2012-12-23 17:53:57
3CMG 29 - ALLERGIC & ANAPHYLACTIC REACTIONS (Revised: November[removed]ANAPHYLAXIS Any acute onset of hypotension or bronchospasm or upper airway obstruction where anaphylaxis is considered

CMG 29 - ALLERGIC & ANAPHYLACTIC REACTIONS (Revised: November[removed]ANAPHYLAXIS Any acute onset of hypotension or bronchospasm or upper airway obstruction where anaphylaxis is considered

Add to Reading List

Source URL: cdn.esa.act.gov.au

Language: English - Date: 2012-12-23 17:54:11
4Microsoft Word - 37-b-01.doc

Microsoft Word - 37-b-01.doc

Add to Reading List

Source URL: media.chop.edu

Language: English - Date: 2014-08-22 15:49:27
5Guidance for Industry  Exercise-Induced Bronchospasm (EIB) — Development of Drugs to Prevent EIB

Guidance for Industry Exercise-Induced Bronchospasm (EIB) — Development of Drugs to Prevent EIB

Add to Reading List

Source URL: www.fda.gov

Language: English
6Page 5 – BLA[removed]XOLAIR® Omalizumab For Subcutaneous Use WARNING Anaphylaxis, presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema

Page 5 – BLA[removed]XOLAIR® Omalizumab For Subcutaneous Use WARNING Anaphylaxis, presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2009-03-31 14:49:50
7Errata to FDA Briefing Document February 23, 2012 Pulmonary-Allergy Drugs Advisory Committee Meeting NDA[removed]: aclidinium bromide for the long-term, maintenance treatment of bronchospasm associated with chronic obstru

Errata to FDA Briefing Document February 23, 2012 Pulmonary-Allergy Drugs Advisory Committee Meeting NDA[removed]: aclidinium bromide for the long-term, maintenance treatment of bronchospasm associated with chronic obstru

Add to Reading List

Source URL: www.fda.gov

Language: English
8Traumatology / Infection / Methicillin-resistant Staphylococcus aureus / Hygiene / Oral rehydration therapy / Allergy / Trauma / Pefloxacin / Medicine / Health / Medical emergencies

Pediatric Medical Complaints after Large-Scale Natural Disasters: Challenges and Adaptations Based Upon Post-Hurricane Responses System Challenges Adaptations to Usual Care Decisions Pulmonary Bronchospasm is common in

Add to Reading List

Source URL: www.jumpstarttriage.com

Language: English - Date: 2012-08-17 14:27:25
9MKrawiec_Allergic Inflammation in Preschool-Toddler Wheezing

MKrawiec_Allergic Inflammation in Preschool-Toddler Wheezing

Add to Reading List

Source URL: www.asthma.ncdhhs.gov

Language: English - Date: 2014-09-02 13:58:15
10Bronchospasm Protocol revised October 2008 Preamble Bronchospasm in patients with asthma or chronic obstructive pulmonary disease presents clinically with shortness of breath and wheezing. This can often be reversed with

Bronchospasm Protocol revised October 2008 Preamble Bronchospasm in patients with asthma or chronic obstructive pulmonary disease presents clinically with shortness of breath and wheezing. This can often be reversed with

Add to Reading List

Source URL: www.gov.mb.ca

Language: English - Date: 2010-05-19 14:32:37